- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
New Variant 'XE' could cause new High Risk Covid Wave, Warns WHO
Geneva: The World Health Organisation (WHO) has issued a warning against a new mutant 'XE' variant of Omicron, that may be more transmissible than any strain of Covid-19 seen before.
This new variant is a recombinant strain, meaning it is a mutant hybrid of the two previous versions of the Omicron variant, BA.1 and BA.2, which spread across the world when it first became a variant of concern, reports Express.co.uk.
Also Read:SARS-CoV-2 variant named 'IHU' emerges in France
According to reports, the new variant is 10 percent more transmissible than the BA.2 subvariant, which is already the most contagious. As per the WHO, BA.2, which is a subvariant of the Omicron strain, is the most dominant strain of the virus, being 86 percent of all sequenced cases attributed to it.
While XE only accounts for a small fraction of the cases, its extremely high transmissibility could mean that it becomes the most dominant strain in the near future.
The WHO has recently issued a report outlining their initial findings of this potentially new variant of concern.
"The XE recombinant (BA.1-BA.2), was first detected in the UK on January 19 and less than 600 sequences have been reported and confirmed since," the report said.
"Early-day estimates indicate a community growth rate advantage of 10 percent as compared to BA.2, however, this finding requires further confirmation," it added.
The global health body noted that until they can detect "significant differences in transmission and disease characteristics, including severity", XE will remain categorized as a part of the Omicron variant.
The UK Health Security Agency (UKHSA) has identified two other new strains besides from the XE variant. These two new recombinant strains have been given the names of XD and XF, with XD being a hybrid of Delta and BA.1 variants of Omicron and XF being a combination of the UK Delta virus and the BA.1 virus. XD has been mostly detected in France, Denmark and Belgium and XF has been predominantly detected in Britain.
"WHO continues to closely monitor and assess the public health risk associated with recombinant variants, alongside other SARS-CoV-2 variants, and will provide updates as further evidence becomes available," the report continued.
Also Read:NeoCov's potential danger to humans requires further study: WHO
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.